Director/Senior Director, Clinical Operations
$180k/y-$265k/y
Crescent Biopharma2 days ago
Highlight
OnsiteFull-timeDirector
Summary
Crescent Biopharma is seeking a Director/Senior Director of Clinical Operations to join their team in Waltham, MA. The role involves planning, executing, and delivering the company’s oncology clinical programs, overseeing all aspects of clinical trial operations.
About the Role
As the Director/Senior Director of Clinical Operations, you will develop and execute the clinical operations strategy for Crescent’s oncology portfolio, provide operational input into clinical development plans, and lead the planning and execution of Phase I-III oncology trials. You will oversee CRO/vendor selection, ensure compliance with regulations, and build a high-performing Clinical Operations team while fostering a culture of accountability and continuous improvement.
About You
Required:
- Bachelor’s degree in a scientific or health-related field, advanced degree preferred.
- 10+ years of drug development and clinical operations experience, including biotech/pharma environments.
- Deep oncology expertise, including early-phase and first-in-human trials.
- Demonstrated leadership of matrix teams and experience building operational infrastructure.
Preferred:
- Experience with novel oncology modalities (e.g., immunotherapy, cell or targeted therapies).
- Strong organizational, problem-solving, and conflict-resolution skills.
- Experience hiring, mentoring, and developing team members.
- Willingness to travel and build relationships with investigators and key opinion leaders.
Benefits
- Competitive compensation, including base salary, performance bonus, and equity.
- 100% employer-paid benefits package.
- Flexible PTO; two, one-week company-wide shutdowns each year.
- Commitment to professional development with access to resources, mentorship, and growth opportunities.
Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. Crescent’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com. Our pipeline originated at Paragon Therapeutics, a biotechnology company founded by Fairmount. Crescent is the fifth company launched to advance assets discovered at Paragon.
Waltham, MA